

REMARKS

Responsive to the action mailed March 28, 2002 Applicants elect the invention of Group II, embodied in claims 18-22, 28-29, 31-32 and 34-64. The election is made without traverse.

Responsive to the requirement to elect a species, Applicants elect the epitope comprising SEQ ID NO:29, claimed as an element of the Markush group of claim 31 and claimed separately in new claim 70. Applicants note that SEQ ID NO's:29, 32, 34 and 35 represent an overlapping group of sequences that in total cover a continuous stretch of 27 amino acid residues.¹


Applicants have presented each of those sequences independently in new claims 70-73. If claim 65 is found allowable, Applicants respectfully request examination of a reasonable number or species represented by claims 31 and 70-73, as well as new claims 74-77.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

7/3/02



John W. Freeman, Esq.
Reg. No. 29,066

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20426503.doc

¹ Taking SEQ ID NO:29 as residues 1-13, then SEEQ ID NO: SEQ ID NO:31 is residues 5-17; SEQ ID NO:32 is residues 9-21; SEQ ID NO: 34 is residues 13-25 and SEQ ID NO:35 is residues 15-27.

18. (Amended four times on 10/14/99, 11/27/01, 1/31/02 and 7/3/02) An anti-human antigen receptor, the receptor being low or not immunogenic in humans, the receptor being obtained by [the method according to any of the methods of claims 1, 14, 15 or 16] a method comprising the steps of:

selecting a combination of functionally rearranged human VH and human VL immunoglobulin chains wherein at least said VH chain is derived from essentially unprimed mature human B-lymphocytes and said VL chain is derived from a naturally occurring human B cell repertoire, said chains being expressed from a recombinant vector and using an in vitro display system for binding to a human antigen.

20. (Amended on 10/14/99 and 7/3/02) The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, said anti-human antigen receptor being specific for a human tumor antigen.

21. (Amended on 10/14/99, 1/31/02, and 7/3/02) The anti-human antigen receptor according to any one of claims 18, 19, 65, 66, 67 or 68, said anti-human antigen receptor being specific for the native human 17-1A antigen.

22. (Amended on 10/14/99, 4/24/01, 5/22/01, 11/27/01, 1/31/02, and 7/3/02) The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, wherein said VH comprises at least one CDR of the amino acid sequence corresponding to nucleotides 1 to 381 of Seq. ID NO: 143 and said VL chain comprises at least one CDR of the amino acid sequence corresponding to nucleotides 1 to 321 of Seq. ID No: 141.

29. (Amended on 10/14/99 and 7/3/02) The anti-human antigen receptor of claim 28 said anti-human antigen receptor being low or not immunogenic [nonn immunogenic] in humans.

31. (Amended five times on 10/14/99, 11/27/01, 12/6/01, 1/31/02 and 7/3/02) The anti-human antigen receptor of claim 28 recognizing an epitope of the extracellular domain of

the 17-1A antigen, said epitope comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 29, [30] 32, 34, 35, 80, 81, 98, 100.

32. (Amended four times on 10/14/99, 11/27/01, 1/31/02 and 7/3/02) The anti-human antigen receptor of claim 28, wherein the VH chain comprises at least one CDR of one of the following two sequences shown in Fig. 7 (corresponding to nucleotides 1 to 381) and Fig. 8 (corresponding to nucleotides 1 to 339) and/or the VL chain comprises at least one CDR of the following two sequences shown in Fig. 6 (corresponding to nucleotides 1 to 321) and Fig. 9 (corresponding to nucleotides 1 to 321).

34. (Added on 10/14/99 and amended 1/31/02 and 7/3/02) The anti-human antigen receptor according to claim 18, 65, 66 or 67, said anti-human antigen receptor comprising a VH chain or at least one CDR.

36. (Added on 10/14/99 and amended 1/31/02 and 7/3/02) The anti-human antigen receptor according to claim 18, 65, 66 or 67, said receptor comprising a VL chain or at least one CDR.

38. (Added on 10/14/99 and amended on 7/3/02) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 18, 65, 66, or 67, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier.

43. (Added on 10/14/99 and amended on 7/3/02) A pharmaceutical composition comprising an anti-human antigen receptor according to claim 18, 65, 66 or 67, comprising at least one CDR and a pharmaceutically acceptable carrier.